Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Watkins and his team have found a new type of genetic change in the DNA of people with hypertrophic cardiomyopathy (HCM) - a silent killer amongst families that can cause sudden death in young people due to the thickening of the heart muscle.

New genetic faults discovered in people with a heart condition that is sometimes inherited in families could transform the diagnosis and treatment of the hidden disease, according to research led by Professor Hugh Watkins.

The work is funded by the British Heart Foundation (BHF) and published in Nature Genetics.

Professor Watkins and his team have found a new type of genetic change in the DNA of people with hypertrophic cardiomyopathy (HCM) - a silent killer amongst families that can cause sudden death in young people due to the thickening of the heart muscle.

It’s now time we think differently about the way this hidden heart condition is detected and treated.
- Professor Hugh Watkins

Better prediction
This ground-breaking discovery, which may be the biggest advance in our knowledge of the genetic basis of the disease in 25 years, will help doctors better predict which family members need to be monitored for the condition and which can be ruled out from further tests or treatment.

For over 25 years, scientists have known that HCM is caused by ‘rare’ genetic faults in the machinery responsible for helping the heart muscle to contract and pump blood around the body. However, researchers and cardiologists have never been able to explain why the condition is so varied amongst family members who have the same rare mutation and why some people without these mutations still go on to develop HCM.

Now, Professor Watkins and his group have discovered that the inheritance of a different type of genetic fault – called ‘common variants’ - not involved in the contractile machinery, form the missing piece to this long-awaited puzzle.
By comparing the DNA of 2,780 people with HCM and 47,486 people without HCM, the team found that the number of these common variants, in combination with the rare mutations, determine whether a person is protected or more susceptible to the disease. Another important consequence is that people who have HCM due to the common variants alone are unlikely to pass the disease onto their children.

HCM affects around 1 in 500 people in the UK, but most people who have it have few, if any, symptoms. If it’s left undetected and untreated it can cause sudden cardiac death, even in young people under 35 years of age

New Genetic Tool

BHF Professor Hugh Watkins, Radcliffe Professor of Medicine and Director of the BHF Centre of Research Excellence, University of Oxford, said: "We now have a new genetic tool that we believe will better predict which members of affected families will have a bad form of the disease, identifying those who need early intervention. It will also take away the worry for many families as it enables us to identify those who are unlikely to pass faulty genes onto their children. This will reduce the need for unnecessary genetic testing and regular follow-ups.”

Professor Sir Nilesh Samani, Medical Director of the BHF and cardiologist, said:
“This research is a major step forward in our understanding of the genetics that underpin hypertrophic cardiomyopathy. It will revolutionise the way we screen people who have family members with this silent killer.

“HCM is one of the most common inherited cardiac conditions, affecting thousands of families across the UK. These discoveries will bring long-awaited answers to many families, and free many individuals from the need for regular clinical checks and the worry of whether they have also inherited the disease.”

The impact of this research is wide-ranging. It also revealed that lowering blood pressure in people with HCM due to these ‘common’ genetic faults could help to prevent the disease from developing.

This research was also supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, the Medical Research Council, Wellcome and the National Heart, Lung, and Blood Institute.

Since 2017, the BHF, through the Miles Frost Fund has invested in a scheme to increase genetic testing for HCM across the UK, investing in staff in inherited cardiac conditions clinics.

Similar stories

Study develops radiotranscriptomic AI analysis to enable virtual heart biopsies

RDM researchers tested the method in COVID-19 patients, to find that the results predicted in-hospital mortality.

BHF Senior Fellowship renewal for Duncan Sparrow could pave the way to revealing unknown causes of heart defects in babies

Congratulations are in order for Associate Professor Duncan Sparrow, who has been awarded a renewal of his British Heart Foundation Senior Basic Science Research Fellowship. The award will fund crucial investigations into little understood environmental risk factors of congenital heart disease, and could one day lead to new therapeutic strategies.

Joaquim Vieira brings heart regeneration research to the public at Pint of Science

Pint of Science is the world’s largest public science festival bringing researchers to local pubs, cafes and spaces to share their scientific discoveries with the public.

DPAG researchers showcased at premier European Society of Cardiology meeting

DPAG scientists across four research groups were highlighted at the major annual European Society of Cardiology basic science conference (FCVB 2022). Congratulations are in order for Dr KC Park on receiving the Young Investigator Award and to Dr Elisabetta Gamen on winning the Moderated Poster Prize.

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.